罗氟司特

罗氟司特，Roflumilast，Cas号 162401-32-3，纯度: 99.86%，是一种口服的长效 4 型磷酸二酯酶抑制剂 (PDE4)，具有抗炎和潜在的抗肿瘤活性。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。

关键词

罗氟司特

所属分类

抑制剂

目录号

T1024

获取报价

猜你喜欢

产品描述
产品组分
文件资源
营销中心
注意事项
FAQ
文献追踪

Roflumilast (APTA 2217) 是一种口服的长效 4 型磷酸二酯酶抑制剂 (PDE4)，具有抗炎和潜在的抗肿瘤活性，作用于PDE4A1，PDEA4，PDEB1和PDEB2，IC50分别为 0.7，0.9，0.7 和 0.2 nM。

生物活性

产品描述	Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.
靶点活性	PDE4A1:0.7 nM, PDE4B2:0.2 nM, PDE4C1:3 nM, PDE4A4:0.9 nM, PDE4B1:0.7 nM
体外活性	在体外实验中,Roflumilast起免疫调节和抗炎活性作用。Rolfumilast对抗CD28和CD3抗体激活的CD4+ T细胞具有抑制作用（IC30：7 nM）,且分别对IL-2（IC20：1 nM）,IL-4（IC30：7 nM）,IL-5（IC25：13 nM）,以及 IFN-v（IC35：8 nM）的合成有抑制作用。在人类嗜中性粒细胞中,Roflumilast抑制LTB4合成（IC50：2 nM）。在酸性粒细胞和中性粒细胞中,Roflumilast对fMLP刺激的ROS形成有抑制作用,IC35 分别是7 nM和4 nM。在单核细胞中,Roflumilast对脂多糖诱导的TNF-α合成有抑制作用（IC40：21 nM）。在源于单核细胞的树突状细胞中,Roflumilast对脂多糖诱导的TNF-α合成有抑制效果（IC20： 5 nM）。
体内活性	在体内实验中,Roflumilast使氧化压力下降.在动物模型中,Roflumilast可一定程度抵抗肺炎（COPD相关）.在暴露于烟草7个月的小鼠肺中, Roflumilast（5 mg/kg/day ）诱导巨噬细胞,中性粒细胞,B细胞,树突状细胞,CD8+ T细胞,CD4+ T 细胞分别减少82%,78%,100%, 48%,88%和98%.博来霉素气管内给药14天后,Roflumilast（5 mg/kg/day ）可适度降低小鼠BAL体液中过氧化氢脂质的增高.在博来霉素处理以后,Roflumilast剂量依赖性降低肺部总羟脯氨酸含量,5 mg/kg/day可抑制47%,并降低肺部纤维化损伤和αI(I)胶原蛋白转录.
激酶实验	PDE activity is determined with some modifications. The assay mixture contain 50 mM Tris (pH 7.4), 5 mM MgCl2, 0.5 μM cAMP or cGMP, and [3H]cAMP or [3H]cGMP (about 30,000 cpm/assay), the indicated concentration of the inhibitor and an aliquot of the enzyme solution at a final assay volume of 200 μL. Stock solutions of the compounds are diluted 1:100 (v/v) in the Tris buffer mentioned above; appropriate dilutions are prepared in 1% (v/v) DMSO/Tris buffer, which are diluted 1:2 (v/v) in the assays to obtain the desired final concentrations of the inhibitors at a DMSO concentration of 0.5% (v/v). DMSO itself affected none of the PDE activities. After preincubation for 5 min at 37°C, the reaction is started by the addition of substrate (cAMP or cGMP) and the assays are incubated for further 15 min at 37°C. Then 50 μL of 0.2 N HCl is added to stop the reaction and the assays are left on ice for about 10 min. Following incubation with 25 μg of 5′-nucleotidase (Crotalus atrox snake venom) for 10 min at 37°C, the assays are loaded on QAE Sephadex A-25 (1 mL of bed volume in Poly-Prep chromatography columns). The columns are eluted with 2 mL of 30 mM ammonium formate (pH 6.0) and the eluate is counted for radioactivity. Results are corrected for blank values (measured in the presence of denatured protein) that are below 5% of total radioactivity. The amount of cyclic nucleotides hydrolyzed did not exceed 30% of the original substrate concentration[3].
别名	罗氟司特, BYK 20869, BY 217, B9302-107, APTA 2217

化学信息

分子量	403.21
分子式	C₁₇H₁₄Cl₂F₂N₂O₃
CAS No.	162401-32-3
Smiles	O(CC1CC1)C2=C(OC(F)F)C=CC(C(NC=3C(Cl)=CN=CC3Cl)=O)=C2
密度	1.471 g/cm3 (Predicted)

产品组分

内容	型号	规格	储存温度
罗氟司特	T1024-01	1mg	-20°C
罗氟司特	T1024-02	5mg	-20°C
罗氟司特	T1024-03	10mg	-20°C
罗氟司特	T1024-04	25mg	-20°C
罗氟司特	T1024-05	50mg	-20°C
罗氟司特	T1024-06	100mg	-20°C
罗氟司特	T1024-07	1mLx10mM in DMSO	-20°C
操作手册	1	1	常温

文件资源

营销中心
注意事项

保存建议厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。
FAQ
1.Hatzelmann A, et al. Pulm Pharmacol Ther, 2010, 23(4), 235-256.

2.Hatzelmann A, et al. J Pharmacol Exp Ther, 2001, 297(1), 267-279.

3.Martorana PA, et al. BMC Pulm Med, 2008, 8:17.

4.Cortijo J, et al. Br J Pharmacol, 2009, 156(3), 534-544.

5.Ding H, et al. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol. 2017 Jul 29.

Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.

Bin Wang, Xiaochan Zhu, ..., Yunfeng Liu

Biochemical and biophysical research commu… | 2024 Jun 14 | 38797152

The Mechanisms Underlying the Pharmacological Effects of GuiPi Decoction on Major Depressive Disorder based on Network Pharmacology and Molecular Docking

Liyuan Chen, Tianyuan Ye, ..., Xiaorui Cheng

Combinatorial chemistry & high throughput … | 2023 Jun 01 | 36045534